News

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late-stage trial at preventing melanoma from returning or spreading. The S&P health-care sector is on track for an all-time closing high, as is Merck, according to data that goes back to 1972. As of Wednesday afternoon, Moderna’s stock had more than doubled, something that a member of the S&P 500 hasn't done in a single day since 2008, according to Dow Jones Market Data.

ZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add

A successful melanoma trial could extend Keytruda's growth story beyond conventional immunotherapy.

Moderna Stock Takes Off After Cancer Trial Win: Why William Blair Just Upgraded MRNA

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.

US equity indexes rose after midday Wednesday after the Treasury Department said it would increase b

(Updates with latest market prices and developments.) US benchmark equity indexes were higher int

Moderna (MRNA) and Merck (MRK) said Wednesday a late-stage trial of an experimental skin cancer trea

Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.2% and th

The result could reshape Moderna's post-vaccine growth story

Broad Market Indicators Broad-market exchange-traded funds IWM and IVV were higher. Actively t

A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.

The treatment combines an mRNA shot with Merck's Keytruda.

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss.

By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its

US equity indexes rose on Wednesday after the Treasury said it would at least double the size of buy

Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.

All three major US stock indexes were up in late-morning trading Wednesday, after the Treasury Depar

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

Shares reach their highest since 2024, still under a third of the 2021 peak

Wall Street Horizon head of corporate event research Christine Short and Sherwood News markets editor Luke Kawa chat with Yahoo Finance's Julie Hyman about Moderna's (MRNA) and Merck's (MRK) melanoma vaccine trial success.

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) and Merck & Co Inc (NYSE:MRK, XETRA:6MK) said Wednesday their personalized mRNA cancer vaccine, intismeran, combined with Merck's Keytruda slowed melanoma recurrence and spread in a Phase 3 trial, in what would be the first randomized late-stage...

Tech stocks faced renewed selling pressure, while healthcare, basic materials, and consumer discretionary stocks rose.

Moderna stock exploded 95% after its mRNA cancer vaccine with Merck scored the first-ever positive Phase 3 result.

Merck (NYSE:MRK) and Moderna report positive Phase 3 results for their individualized mRNA-based melanoma vaccine in combination with KEYTRUDA. The trial is the first successful Phase 3 study of an individualized mRNA cancer vaccine and shows improved recurrence-free and distant metastasis-free survival for melanoma patients. The data indicate a potential new commercial and clinical use for mRNA technology beyond infectious diseases and may widen Merck's oncology pipeline. This progress in...

Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%. A late-stage trial of its experimental, vaccine-based treatment, called Intismeran, reduced skin cancer re-growth and stopped it spreading to other parts of the body. Intismeran combines an immunotherapy drug created by German pharmaceutical company Merck with a Moderna mRNA vaccine, a type of shot authorised widely to treat COVID-19.